Is M65 really better than M30 as a biomarker of hepatic fibrosis?

Hepatology

Volumn 55, Issue 2, 2012, Pages 654-

  Yilmaz, Yusuf ^a,b   Kurt, Ramazan ^a,b  

^a MARMARA UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; BIOLOGICAL MARKER; M 65; UNCLASSIFIED DRUG;

APOPTOSIS; BLOOD LEVEL; CHRONIC LIVER DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FALSE NEGATIVE RESULT; FATTY LIVER; HEPATITIS C VIRUS; HUMAN; LETTER; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

FATTY LIVER; FEMALE; HUMANS; KERATIN-18; LIVER CIRRHOSIS; MALE;

EID: 84856406022     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25520     Document Type: Letter

References (6)

1. Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. HEPATOLOGY 2012; 55: 455-464.
2. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837-844.
3. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. HEPATOLOGY 1996; 24: 289-293.
4. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
5. Yilmaz Y. Cytokeratins in hepatitis. Clin Chim Acta 2011; 412: 2031-2036.
6. Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18-the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 2009; 30: 1103-1109.